Brief: Enlivex Announces Completion Of Enrollment Of Its Phase Ii Trial Evaluating Allocetra In Patients With Sepsis
20/12/2023 13:08
Dec 20 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES COMPLETION OF ENROLLMENT OF ITS PHASE II
TRIAL
EVALUATING ALLOCETRA IN PATIENTS WITH SEPSIS
* ENLIVEX THERAPEUTICS LTD - TOPLINE DATA EXPECTED IN LATE
Q1 2024
Source text for Eikon: ID:nGNXbk3Bxh
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment